# A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC

> **NCT07726992** · PHASE3 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 750 (estimated)

## Conditions studied

- Papillary-Only Non-muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** SHR-1501+BCG
- **DRUG:** Placebo +BCG

## Key facts

- **NCT ID:** NCT07726992
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2029-12
- **Final completion:** 2030-08
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726992, "A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*